Table 2 Base case results for EVE plus EXE vs. BEV plus PACL and BEV plus CAPE for the treatment of ER+ mBC patients
Incremental analysis | |||||
|---|---|---|---|---|---|
Outcomes | EVE plus EXE | BEV plus PACL | BEV plus CAPE | BEV plus PACL | BEV plus CAPE |
Treatment and administration costs* | 25,727 € | 32,960 € | 25,832 € | −7,233 € | −105 € |
AE costs (grade 3/4)* | 62 € | 5 € | 1 € | 57 € | 61 € |
Pre-progression background costs* | 1,000 € | 3,744 € | 3,946 € | −2,744 € | −2,946 € |
Post-progression background costs* | 27,495 € | 30,534 € | 32,308 € | −3,039 € | −4,813€ |
Terminal care costs* | 737.51 € | 736.41 € | 734,77 € | 1.10 € | −2.74 € |
Total costs* | 55,022 € | 67,980 € | 62,822 € | −12,958 € | −7,800 € |
QALYS*: Pre-progressed | 0.648 | 0.494 | 0.456 | 0.154 | 0.192 |
QALYS*: Post-progressed | 1.076 | 1.195 | 1,264 | −0.119 | −0.188 |
Total QALYS* | 1.724 | 1.689 | 1,720 | 0.035 | 0.004 |
Life years†: Pre-progressed | 0.899 | 0.689 | 0.604 | 0.210 | 0.295 |
Life years†: Post-progressed | 2.422 | 2.679 | 2.833 | −0.257 | −0.411 |
Total undiscounted life years† | 3.321 | 3.368 | 3.437 | −0.047 | −0.116 |
Life years*: Pre-progressed | 0.876 | 0.675 | 0.594 | 0.201 | 0.282 |
Life years*: Post-progressed | 2.167 | 2.406 | 2.546 | −0.240 | −0.379 |
Total discounted life years* | 3.043 | 3.082 | 3.140 | −0.039 | −0.097 |
Incremental cost per QALY | Dominant | Dominant | |||
Incremental cost per LY | Less effective | Dominant | |||
*discounted †undiscounted | |||||